@article{3076260,
    title = "Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue",
    author = "Theoharides, T.C. and Cholevas, C. and Polyzoidis, K. and Politis, A.",
    journal = "BioFactors",
    year = "2021",
    volume = "47",
    number = "2",
    pages = "232-241",
    publisher = "Blackwell Publishing Inc.",
    issn = "0951-6433, 1872-8081",
    doi = "10.1002/biof.1726",
    keywords = "antineoplastic agent;  luteolin;  cytokine;  luteolin, chemotherapy;  clouding of consciousness;  coronavirus disease 2019;  disease association;  human;  nervous system inflammation;  priority journal;  Review;  brain;  cognitive defect;  complication;  drug effect;  fatigue;  genetics;  mast cell;  pathogenicity;  pathophysiology;  virology, Brain;  Cognitive Dysfunction;  COVID-19;  Cytokines;  Fatigue;  Humans;  Luteolin;  Mast Cells;  SARS-CoV-2",
    abstract = "COVID-19 leads to severe respiratory problems, but also to long-COVID syndrome associated primarily with cognitive dysfunction and fatigue. Long-COVID syndrome symptoms, especially brain fog, are similar to those experienced by patients undertaking or following chemotherapy for cancer (chemofog or chemobrain), as well in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) or mast cell activation syndrome (MCAS). The pathogenesis of brain fog in these illnesses is presently unknown but may involve neuroinflammation via mast cells stimulated by pathogenic and stress stimuli to release mediators that activate microglia and lead to inflammation in the hypothalamus. These processes could be mitigated by phytosomal formulation (in olive pomace oil) of the natural flavonoid luteolin. © 2021 International Union of Biochemistry and Molecular Biology"
}